Covicept Therapeutics initiates a Phase 2 clinical study with PJS-539, an oral small molecule for the treatment of patients with COVID-19 (SARS-CoV-2) Covicept has initiated a Phase 2 multi-center
Covicept Therapeutics initiates a Phase 2 clinical study with PJS-539, an oral small molecule for the treatment of patients with COVID-19 (SARS-CoV-2) | Comunicados | Edición USA efe.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from efe.com Daily Mail and Mail on Sunday newspapers.
Posted on 7468
Forbion, a leading European life sciences venture capital firm, today announces a $2.3m seed investment in newly formed CoviCept Therapeutics, Inc. (“CoviCept”), a California-based company that is developing a small molecule that inhibits the replication of SARS-CoV-2 (COVID-19) and other RNA viruses.
CoviCept’s lead molecule has a unique mechanism of action that is based on interference of a host cell protein and is therefore expected to have a low risk of viral resistance. It has been demonstrated to inhibit SARS-CoV-2 replication in a relevant mammalian model at a clinically relevant dose. A manufacturing process for the lead compound has been established and it has demonstrated good bioavailability and safety in humans in phase 1 studies.